You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 202315009
Dec 20233406
Jan 20241902
Feb 20242401
Mar 20241600
Apr 20242001
May 20242004
Jun 20241201
Jul 20241201
Aug 20241606
Sep 20242203
Oct 202424012
Nov 20241208
Dec 2024407
Jan 20252205
Feb 2025206
Mar 2025004
Apr 2025002
May 20250010
Jun 2025003
Total409091